MOD3 Pharma
MOD3 Pharma works with pharmaceutical partners to improve the solubility of hard-to-dose therapeutics. The company’s core
New Name, Same Team
- Rebranded in 2025 from Enteris BioPharma to MOD3 Pharma.
The new name better aligns with MOD3 Pharma’s mission of supporting Module 3 completion for IND/IMPD submissions and accelerating clinical development. - A subsidiary of SWK Holdings Corp, operating as a fully integrated CDMO specializing in innovative OINDP drug delivery solutions.
Chemistry, Manufacturing & Controls (CMC) Expertise in Orally Inhaled & Nasal Drug Product (OINDP)
- Decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP).
- Transforming investigational drugs into clinic-ready products.
- Specialized capabilities for early-phase clinical supplies, including Spray drying, Semi-automated filling and assembly, Single-dose powder & liquid nasal systems, and Bi-dose and multidose nasal devices
Contract Development & Manufacturing Organization (CDMO) Platform
- Dedicated to supporting clients through Phase 1 & 2 clinical trials.
- Expertise in drug formulation, process development, and scalable manufacturing for OINDP.
- Bridging the gap between early-stage development and commercial readiness.
Strong Team; Positioned for Success
- Leadership team with over a century of collective experience in pharmaceuticals and biotechnology.
- Commitment to innovation, technical excellence, and strategic industry partnerships.
- Addressing key challenges: Risk. Time. Cost. – The trifecta of hurdles in drug development.
- Your project matters—not just to you, but to the patients relying on your therapy.